List of contents: eTable 1: Definitions on comorbidity and concomitant medication according to ICD-10 codes and ATC-codes. eTable 2: Thromboembolic event rates according to different levels of baseline CHA 2 DS 2 -VASc score stratified by methodological approach. eTable 3: Primary diagnosed thromboembolic event rates according to different levels of baseline CHA 2 DS 2 -VASc score stratified by methodological approach. eTable 4: Primary diagnosed thromboembolic event rates in relation to different methodological approaches stratified according to cut-off values of stroke risk based on the CHA 2 DS 2 -VASc score. eTable 5: Thromboembolic event rates according to different levels of baseline CHA 2 DS 2 -VASc score using data from previous five years (2009 -2014).
eTable 1: Definitions on comorbidity and concomitant medication according to ICD-10 codes and ATC-codes. Conditions marked with † was used in the calculation of the CHA 2 DS 2 -VASc score. Calcium channel blockers C07F, C08, C09BB, C09DB
Renin-angiotensin system inhibitors C09 * We identified subjects with hypertension † from combination treatment with at least two of the following classes of antihypertensive drugs:
I. Alpha adrenergic blockers (C02A, C02B, C02C)
II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA,
C09XA52)
III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)
IV. Beta blockers (C07)
V. Calcium channel blockers (C07F, C08, C09BB, C09DB)
VI. Renin-angiotensin system inhibitors (C09). 
